Free Writing Prospectus filed pursuant to Rule 433

Relating to the Preliminary Prospectus Supplement dated June 5, 2017 to the Prospectus dated November 22, 2016

Registration Statement No. 333-214756


AstraZeneca PLC


US$250,000,000 Floating Rate Notes due 2022


Amended and Restated Final Term Sheet1


Issuer: AstraZeneca PLC
Trade Date: June 5, 2017
Settlement Date: June 12, 2017 (T+5)
Expected Ratings: Moody’s: A3 (stable); S&P: A- (negative)


US$250,000,000 Floating Rate Notes due 2022: 

Security Type: Senior Notes
Aggregate Principal Amount: $250,000,000
Maturity Date: June 10, 2022
Interest Rate: For the first interest period, LIBOR as determined on June 8, 2017 plus the Spread. Thereafter, LIBOR as determined on the applicable Interest Determination Date (as defined below) plus the Spread.
Spread: 62 basis points
Price to Public: 100.000% of face amount
Interest Payment Dates: March 10, June 10, September 10 and December 10 of each year, commencing September 10, 2017.
Interest Reset Dates: March 10, June 10, September 10 and December 10 of each year, commencing September 10, 2017.

Floating Rate Interest Periods

From and including an Interest Reset Date to but excluding the immediately succeeding Interest Reset Date (or the Maturity Date, if earlier).


Interest Determination Dates

Two London business days prior to each Interest Reset Date.


Gross Proceeds to Issuer:


Underwriting Discount and Commissions: 0.350% of face amount
Net Proceeds to Issuer: $249,125,000
Redemption Provisions:  
Optional Tax Redemption: In the event of various tax law changes and other limited circumstances that require the Company to pay additional amounts, in whole but not in part, at a price




1Explanatory note: this Amended and Restated Final Term Sheet amends, restates and supersedes in its entirety AstraZeneca PLC’s Final Term Sheet dated June 5, 2017, only with respect to the section entitled “US$250,000,000 Floating Rate Notes due 2022”, to correct the Interest Determination Date for the first interest period as indicated opposite the caption “Interest Rate”.


  equal to 100% of the principal amount plus accrued interest thereon to but excluding the redemption date.
CUSIP: 046353 AP3
ISIN: US046353AP31
Joint Book-Running Managers:

Barclays Capital Inc.

HSBC Securities (USA) Inc.

Merrill Lynch, Pierce, Fenner & Smith Incorporated
Morgan Stanley & Co. LLC




Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.


The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. at toll-free 1-888-603-5847, HSBC Securities (USA) Inc. at toll-free 1-866-811-8049, Merrill Lynch, Pierce, Fenner & Smith Incorporated at toll-free 1-800-294-1322, or Morgan Stanley & Co. LLC at toll-free 1-866-718-1649.


Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email system.